Clinical Trial for Evaluating the Efficacy and Safety of BCG for Therapeutic Use in the Prevention of Postoperative Recurrence of Medium/High-risk Non-muscle Invasive Bladder Cancer (NMIBC)

This study is evaluating the safety and effectiveness of BCG bladder instillation therapy — a standard but important treatment where a weakened tuberculosis bacteria is placed into the bladder to stimulate the immune system against cancer — in Chinese patients with medium to high risk non-muscle invasive bladder cancer (NMIBC). This type of bladder cancer has not grown into the muscle wall and carries a meaningful risk of recurrence after surgery. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with medium or high-risk non-muscle invasive bladder cancer (T1, Ta, or Tis stage) - You have had a complete transurethral resection of the bladder tumor (TURBt), with all visible tumor removed - A second TURBt procedure was performed or is planned if required by your condition - You are ready to begin BCG instillation therapy **You may NOT be eligible if...** - Your bladder cancer has grown into the muscle layer (muscle-invasive disease) - You have had other chemotherapy instillations recently (except specified agents) - You have contraindications to BCG therapy - You cannot complete the study follow-up visits Talk to your doctor to see if this trial is right for you.